We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Orion Corporation and Bayer have submitted a marketing application in Europe for use of darolutamide in patients with a certain type of prostate cancer.
Novan, Inc. today announced that the Company has established a strategic alliance with Orion Corporation, a Finnish full-scale pharmaceutical company with broad experience in manufacturing.....